Entrada Therapeutics Price Target Maintained With a $25.00/Share by Oppenheimer
Entrada Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25
Entrada Therapeutics Inc (TRDA) Gets a Buy From Oppenheimer
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $18 Price Target
Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20
Entrada Therapeutics Analyst Ratings